38 results on '"Recurrent small cell lung cancer"'
Search Results
2. Prognostic factors and outcome of reirradiation for locally recurrent small cell lung cancer-a multicenter study
3. Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer
4. Albumin-bound paclitaxel plus PD-1/PD-L1 inhibitor versus second-line chemotherapy for patients with recurrent small cell lung cancer
5. A Double Check on Cancer Progression: Combined Nivolumab and Ipilimumab for Recurrent Small Cell Lung Cancer
6. Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience
7. Immune Checkpoint Inhibitors in the Management of Lung Cancer
8. Gene Profiling in Recurrent Small Cell Lung Cancer
9. P2.12-01 Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study
10. Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC)
11. Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer
12. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
13. MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
14. Safety of belotecan as second-line treatment for recurrent small cell lung cancer: A phase IIb randomized multicenter study
15. PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON
16. Approaches for Estimating the Comparative Efficacy of Treatments for Patients with Recurrent Small Cell Lung Cancer (SCLC) within Connected and Disconnected Networks of Evidence
17. Management of Recurrent Small Cell Lung Cancer
18. An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
19. Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC)
20. Weekly topotecan for recurrent small cell lung cancer - a retrospective Anatolian Medical Oncology Group study
21. Hematologic toxicity of amrubicin monotherapy in recurrent small-cell lung cancer
22. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
23. The Role of Radiotherapy for Extensive-Stage and Recurrent Small Cell Lung Cancer
24. Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
25. 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC)
26. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
27. Recurrent small cell lung cancer presenting as bilateral adnexal masses
28. A Phase II Study of 5-Fluorouracil Plus High-Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung Cancer
29. Clinical outcomes of patients with recurrent small cell lung cancer receiving third-line chemotherapy
30. Case 95 Recurrent Small Cell Lung Cancer
31. The Relationship of Serum NSE Level and Metabolic Tumor Volume or Total Lesion Glycolysis as Determined by FDG PET in Patients With Recurrent Small Cell Lung Cancer
32. Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study
33. 147PD A PHASE II STUDY OF WEEKLY PACLITAXEL PLUS GEMCITABINE AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OR RECURRENT SMALL CELL LUNG CANCER (SCLC)
34. Phase II trial of weekly topotecan with docetaxel in recurrent small cell lung cancer (Aultman Lung 01)
35. Phase II study of irinotecan and paclitaxel for patients with recurrent small cell lung cancer (SCLC)
36. P-765 Phase I study of weekly topotecan (T) in recurrent small cell lung cancer (SCLC)
37. Obstructive jaundice as a recurrent symptom of small cell lung cancer
38. Treatment of refractory or recurrent small cell lung cancer (SCLC) with cyclophosphamide, cisplatin and vincristine (a non-cross-resistant regimen)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.